SOLICITATION NOTICE
B -- Post-Market Bioequivalence of Generic Drug Product
- Notice Date
- 12/5/2023 1:43:04 PM
- Notice Type
- Solicitation
- NAICS
- 541715
— Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Contracting Office
- FDA CENTER FOR DRUG EVALUATION AND RESEARCH Silver Spring MD 20993 USA
- ZIP Code
- 20993
- Solicitation Number
- 75F40124R00023
- Response Due
- 1/12/2024 7:00:00 AM
- Archive Date
- 01/27/2024
- Point of Contact
- Telisha WIlson
- E-Mail Address
-
telisha.wilson@fda.hhs.gov
(telisha.wilson@fda.hhs.gov)
- Small Business Set-Aside
- 8A 8(a) Set-Aside (FAR 19.8)
- Description
- Post-Market Bioequivalence of Generic Drug Product Questions are due 10AM EST 12/22/2023 Proposals are due 10AM EST 01/12/2024
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/ba2ea7e189cc40f7a70036afd9a4c03b/view)
- Record
- SN06902555-F 20231207/231205230046 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |